Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th Panel of the Federal Regional Court of the 1st Region (“TRF-1”) in relation to three judicial proceedings involving the Volta Grande Gold Project (the “Project”), located in Pará State, Brazil. DPU Appeal Dismissed One of the matters heard concerned the appeal filed by the Federal Public Defender's Office (“DPU”) and an indigenous association against a lower court decision that had dismissed for procedural reasons a civil public action related to the alleged need for supplementation of the Indigenous Component Study (“ECI”) and the performance of additional public consultation procedures.

Boston Scientific Corporation (NYSE:BSX) on Tuesday reported positive pivotal trial data for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, with the device meeting both primary safety and effectiveness goals in patients with severely calcified coronary artery disease.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD).

On May 18, 2026, Boston Scientific Corp (BSX) shares rose 6.2%, bringing the current price to $55.92. This increase comes amid a challenging year for the compan

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

Boston Scientific Corporation (NYSE:BSX) said it invested $1.5 billion in privately held MiRus, securing an approximately 34% equity stake and an exclusive option to acquire the company's investigational transcatheter aortic valve replacement (TAVR) business.

U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held ​MiRus LLC in return for a 34% equity ‌stake and potential access to the startup's heart-valve business.

MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization.